相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes
Yanheng Wu et al.
NANOMEDICINE (2019)
Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions
Jianping Liu et al.
SMALL (2019)
Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
Anna Galstyan et al.
NATURE COMMUNICATIONS (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments
Yang Du et al.
CANCER LETTERS (2018)
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy
Chih-Sheng Chiang et al.
NATURE NANOTECHNOLOGY (2018)
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
Wen Cheng et al.
ONCOGENESIS (2018)
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Qin Fan et al.
ADVANCED FUNCTIONAL MATERIALS (2018)
Immune Checkpoint Inhibitor Toxicity
David J. Palmieri et al.
CURRENT ONCOLOGY REPORTS (2018)
Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Sara Musetti et al.
ACS NANO (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy
Quanyin Hu et al.
NATURE BIOMEDICAL ENGINEERING (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer
Zhenliang Sun et al.
DRUG DELIVERY (2018)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model
Qi Liu et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The new era of nanotechnology, an alternative to change cancer treatment
Ancuta Jurj et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y. Xu-Monette et al.
FRONTIERS IN IMMUNOLOGY (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy
Rinat Meir et al.
ACS NANO (2017)
Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth
Gijung Kwak et al.
ACS NANO (2017)
Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival
Tyler J. Goodwin et al.
BIOMATERIALS (2017)
Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth
Alyssa K. Kosmides et al.
ACS NANO (2017)
Novel Approach of Using Near-Infrared Responsive PEGylated Gold Nanorod Coated Poly(L-lactide) Microneedles to Enhance the Antitumor Efficiency of Docetaxel-Loaded MPEG-PDLLA Micelles for Treating an A431 Tumor
Ying Hao et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer
Jun Xu et al.
ACS NANO (2017)
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Arjun Vasant Balar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity
Yongkui Li et al.
ONCOIMMUNOLOGY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation
Shi-Yong Li et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
Chao Wang et al.
NANO LETTERS (2016)
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Katrin Klocke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy
Hong-Jun Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Improving the clinical impact of biomaterials in cancer immunotherapy
Joshua M. Gammon et al.
ONCOTARGET (2016)
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Noha Abdel-Wahab et al.
PLOS ONE (2016)
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy
Hao-Nan Chang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsaEuro
T. W. Chen et al.
ANNALS OF ONCOLOGY (2015)
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
Sima Rahimian et al.
BIOMATERIALS (2015)
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia
Fabienne McClanahan et al.
BLOOD (2015)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012
Kei Muro et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
Alison M. Paterson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
Matthew M. K. Chan et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ovarian Cancer Immunotherapy Using PD-L1 siRNA Targeted Delivery from Folic Acid-Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing
Pei Yun Teo et al.
ADVANCED HEALTHCARE MATERIALS (2015)
Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade
Shirwa Sheik Ali et al.
JAMA DERMATOLOGY (2015)
Nanoparticle-Based Immunotherapy for Cancer
Kun Shao et al.
ACS NANO (2015)
B7H1/CD80 Interaction Augments PD-1-Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease
Ruishu Deng et al.
JOURNAL OF IMMUNOLOGY (2015)
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He et al.
SCIENTIFIC REPORTS (2015)
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Yuchen Fan et al.
VACCINES (2015)
Smart Nanodevice Combined Tumor-Specific Vector with Cellular Microenvironment-Triggered Property for Highly Effective Antiglioma Therapy
Kun Shao et al.
ACS NANO (2014)
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
Christian J. Maine et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
Leena Gandhi et al.
CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Yanping Xiao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances
Fenghua Meng et al.
NANOMEDICINE (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype
Griselda V. Zuccarino-Catania et al.
NATURE IMMUNOLOGY (2014)
The immune checkpoint inhibitors: where are we now?
Rachel Webster
NATURE REVIEWS DRUG DISCOVERY (2014)
Nanoparticle approaches against bacterial infections
Weiwei Gao et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes
Laura Jeanbart et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475
Richard Kefford et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
pH-Responsive Nanoparticle Vaccines for Dual-Delivery of Antigens and Immunostimulatory Oligonucleotides
John T. Wilson et al.
ACS NANO (2013)
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
Uma Prabhakar et al.
CANCER RESEARCH (2013)
Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
Yan Feng et al.
CLINICAL CANCER RESEARCH (2013)
Chemokine receptor CXCR4: Role in gastrointestinal cancer
Lucia Lombardi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Xiaoxiao Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Codelivery of VEGF siRNA and Gemcitabine Monophosphate in a Single Nanoparticle Formulation for Effective Treatment of NSCLC
Yuan Zhang et al.
MOLECULAR THERAPY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Polyethylenimines for siRNA and miRNA delivery in vivo
Sabrina Hoebel et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2013)
Micro and Nanoparticle-Based Delivery Systems for Vaccine Immunotherapy: An Immunological and Materials Perspective
Jardin Leleux et al.
ADVANCED HEALTHCARE MATERIALS (2013)
Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells
Eric F. Tewalt et al.
BLOOD (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Sebastien Taurin et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor
Jun Li et al.
JOURNAL OF CONTROLLED RELEASE (2012)
A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases
Mark J. Ernsting et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
Nikolaos Patsoukis et al.
SCIENCE SIGNALING (2012)
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
Shamudheen M. Rafiyath et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Overall Survival and PD-L1 Expression in Metastasized Malignant Melanoma
Jules Gadiot et al.
CANCER (2011)
Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David J. Andorsky et al.
CLINICAL CANCER RESEARCH (2011)
Lipoic Acid Modified Low Molecular Weight Polyethylenimine Mediates Nontoxic and Highly Potent in Vitro Gene Transfection
Meng Zheng et al.
MOLECULAR PHARMACEUTICS (2011)
Programming the magnitude and persistence of antibody responses with innate immunity
Sudhir Pai Kasturi et al.
NATURE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
Michael A. Curran et al.
PLOS ONE (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
Qing Zhou et al.
BLOOD (2010)
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Jang-June Park et al.
BLOOD (2010)
Synthetic therapeutic peptides: science and market
Patrick Vlieghe et al.
DRUG DISCOVERY TODAY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
To PEGylate or not to PEGylate, that is not the question
Kinam Park
JOURNAL OF CONTROLLED RELEASE (2010)
Local Release of Highly Loaded Antibodies from Functionalized Nanoporous Support for Cancer Immunotherapy
Chenghong Lei et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms
Wataru Ise et al.
NATURE IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
Nitya Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes
You-Yeon Won et al.
JOURNAL OF CONTROLLED RELEASE (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Steven D. Perrault et al.
NANO LETTERS (2009)
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Vijayakumar Velu et al.
NATURE (2009)
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
Brian T. Fife et al.
NATURE IMMUNOLOGY (2009)
Therapeutic nanoparticles for drug delivery in cancer
Kwangjae Cho et al.
CLINICAL CANCER RESEARCH (2008)
Interaction of human PD-L1 and B7-1
Manish J. Butte et al.
MOLECULAR IMMUNOLOGY (2008)
Nanoparticle-mediated cellular response is size-dependent
Wen Jiang et al.
NATURE NANOTECHNOLOGY (2008)
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
Yasushi Onishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
CTLA-4 trafficking and surface expression
Elke Valk et al.
TRENDS IN IMMUNOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues
Mary E. Keir et al.
JOURNAL OF IMMUNOLOGY (2007)
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Raymond M. Wong et al.
INTERNATIONAL IMMUNOLOGY (2007)
PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched forVH11/VH12 and phosphatidylcholine binding
Xuemei Zhong et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
Monica V. Goldberg et al.
BLOOD (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity
Tomofumi Uto et al.
JOURNAL OF IMMUNOLOGY (2007)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts
Junko Hori et al.
JOURNAL OF IMMUNOLOGY (2006)
Regulation of T cell activation and tolerance by PDL2
Yongliang Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro
C Blank et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release
C. Bouissou et al.
PHARMACEUTICAL RESEARCH (2006)
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
OC Farokhzad et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Mast cells enhance T cell activation: Importance of mast cell costimulatory molecules and secreted TNF
S Nakae et al.
JOURNAL OF IMMUNOLOGY (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes
ME Keir et al.
JOURNAL OF IMMUNOLOGY (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo
SE Sandner et al.
JOURNAL OF IMMUNOLOGY (2005)
NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells
A Saudemont et al.
BLOOD (2005)
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
HC Probst et al.
NATURE IMMUNOLOGY (2005)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
B7-H1 determines accumulation and deletion of intrahepatic CD8+ T lymphocytes
HD Dong et al.
IMMUNITY (2004)
Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors
T Fifis et al.
JOURNAL OF IMMUNOLOGY (2004)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
YE Latchman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases
MC Brunner-Weinzierl et al.
ARTHRITIS RESEARCH & THERAPY (2004)
Memory CD8 T-cell differentiation during viral infection
EJ Wherry et al.
JOURNAL OF VIROLOGY (2004)
Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes
ND Sonawane et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses
SC Liang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
N Watanabe et al.
NATURE IMMUNOLOGY (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells
C Pasare et al.
SCIENCE (2003)
Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production
JA Brown et al.
JOURNAL OF IMMUNOLOGY (2003)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
JL Riley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
T-cell regulation by CD28 and CTLA-4
ML Alegre et al.
NATURE REVIEWS IMMUNOLOGY (2001)
Platelet activation: assessment and quantification
S Kamath et al.
EUROPEAN HEART JOURNAL (2001)
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
JCD Schwartz et al.
NATURE (2001)
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
CC Stamper et al.
NATURE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
G Steinbach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Facilitation of β selection and modification of positive selection in the thymus of PD-1-deficient mice
H Nishimura et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
